Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 13, 2025The British Journal of PsychiatryOpen Access

Economic evaluation of different haematological monitoring schemes for patients with treatment-resistant schizophrenia using clozapine

View Full Paper
Ask AI
Bookmark
Share

Authors

FDFreya DiederichEOEbenezer OloyedeDTDavid Taylor

Discussion

Loading...

Member takes

Implication

Cost-effectiveness analysis reveals extended haematological monitoring reduces costs for clozapine patients, indicating potential benefits for quality of life.

Key Points

  • This research evaluates the cost-effectiveness and budget impact of haematological monitoring schemes for clozapine use in treatment-resistant schizophrenia.
  • Conducted a cost-effectiveness and budget impact analysis from the healthcare system perspective over three years.
  • Compared current UK monitoring practice with extended haematological monitoring and revision of ANC criteria.
  • Estimated costs and quality-adjusted life years (QALYs) using a semi-Markov model with a simulated cohort of 100,000 adults with TRS.
  • Extended monitoring leads to lower average costs per patient (£5,569.77 vs. £6,388.34) without compromising QALYs (795.79 vs. 795.83 days).
  • Revising ANC criteria does not significantly reduce costs (£6,390 vs. £6,388.34) but slightly increases QALYs (797.08 vs. 795.83 days).
  • The combined strategy of extended monitoring and revised ANC criteria is most effective with lower costs (£5,548.50) and improved QALYs (797.03 days) compared to current practice.

Cite This Study

Diederich et al. (2025) studied this question.

synapsesocial.com/papers/692523bbc0ce034ddc35494chttps://doi.org/10.1192/bjp.2025.10424
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Clozapine monitoring at a specialised psychiatric hospital: A retrospective chart review2023 · 2 citations
  2. 2Clozapine-related neutropenia and agranulocytosis in Korea: 2025 update for rethinking the role of monitoring system2026
  3. 3Baseline neutrophil count, benign ethnic neutropenia risk, and clozapine haematological monitoring: A multi-ethnic retrospective cohort study from the United Arab Emirates2026
  4. 4Potential Indicators of Bone Marrow Suppression in Patients with Schizophrenia Receiving Clozapine: Platelet-Large Cell Ratio and Immature Granulocytes2024
  5. 5Identifying clinically relevant agranulocytosis in people registered on the UK clozapine Central Non-Rechallenge Database: retrospective cohort study2024 · 6 citations